跳至主要内容
临床试验/NCT04415047
NCT04415047进行中(未招募)不适用

A Study to Assess Safety and Effectiveness of the JenaValve Trilogy™ Heart Valve System in the Treatment of High Surgical Risk Patients With Symptomatic, Severe Aortic Regurgitation (AR)

JenaValve Technology, Inc.59 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2020年5月22日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
180
试验地点
59
主要终点
All Stroke

研究概览

简要总结

To collect information about treatment for symptomatic severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.

详细描述

This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a minimally invasive procedure designed to replace the aortic valve inside the heart. In this study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat symptomatic severe aortic regurgitation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with severe aortic regurgitation (AR).
  • Patient at high risk for open surgical valve replacement
  • Patient symptomatic according to NYHA functional class II or higher
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.

排除标准

  • Congenital uni or bicuspid aortic valve morphology
  • Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  • Endocarditis or other active infection
  • Need for urgent or emergent TAVR procedure for any reason
  • Cardiogenic shock or hemodynamic instability requiring inotropic support or ventricular assist device
  • Severe mitral regurgitation

结局指标

主要结局

All Stroke

时间窗: 30 days

Number of patients that had a stroke

Acute Kidney Injury

时间窗: 30 days

Number of patients that had these events

Major Vascular Complications

时间窗: 30 days

Number of patients that had these events

Surgery/intervention related to the device

时间窗: 30 days

Number of patients that had these events

Permanent pacemaker implantation

时间窗: 30 days

Number of patients that had these events

All-Cause Mortality at 1 Year

时间窗: 1 year

All-cause mortality within the first 12 months post index procedure

Major Bleeding

时间窗: 30 days

Number of patients that had any of these events

Total aortic regurgitation

时间窗: 30 days

Number of patients that had these events

次要结局

  • KCCQ(1 year)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (59)

Loading locations...

相似试验

相关资讯